-
Story /I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.
-
Ad hoc release /Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…
-
Story /When Carl was diagnosed with metastatic prostate cancer, he and his wife Arlene began navigating his cancer journey while still looking to enjoy their retirement – hoping to remain active with family and friends in their retirement community.
-
Story /Pneumonia causes around 2 million child deaths per year globally and the burden is especially heavy in a country like Bangladesh, where a third of the population is aged 14 or below.
-
Story /Researchers race to put hydroxychloroquine to the test in a large study.
-
Press release /Aktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
-
Press release /The European & Developing Countries Clinical Trials Partnership (EDCTP) grants EUR 10 million over five years to "WANECAM 2" a unique collaboration between antimalarial drug researchers in…
-
Press release /Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
-
Story /Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.
Pagination
- ‹ Previous page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- …
- 168
- › Next page